Effect of transcutaneous electrical stimulation of PC-5 and PC-6 acupoints on induced hypotension and microcirculation

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400087366

Enrollment

Unknown

Registered

2024-07-25

Start date

2024-08-01

Completion date

Unknown

Last updated

2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypotension

Interventions

Acupoint group:transcutaneous electrical acupoint stimulation

non-acupoint group:transcutaneous electrical acupoint stimulation

control group:none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Part 1 Experiment: 1. Patients diagnosed by our research center who require CRS+HIPEC surgery; 2. Age range from 18 to 65 years old; 3. The heart and other organs can tolerate surgery; 4. ASA classification II-III levels; 5. Voluntarily participate and have signed an informed consent form. Part 2 Experiment: 1. Patients diagnosed by our research center who require CRS+HIPEC surgery; 2. Age range from 18 to 75 years old; 3. Weakness score of 4-6 levels; 4. Voluntarily participate and have signed an informed consent form.

Exclusion criteria

Exclusion criteria: Part 1 Experiment: 1. Recently suffering from myocardial infarction or congestive heart failure; 2. Congenital heart disease or history of cardiac surgery, heart conduction block, frequent atrial/ventricular premature beats, atrial fibrillation and other serious arrhythmias; 3. Patients with preoperative blood pressure>160/100mmHg or diastolic blood pressure>100mmHg, or blood pressure1.2 ULN; 7. Severe cerebrovascular diseases such as cerebral ischemia, cerebral vascular stenosis, or arteriosclerosis. Part 2 Experiment: 1. Severe liver and kidney dysfunction; 2. Patients with implantable medical devices such as pacemakers; 3. Patients with infection at acupoints; 4. There are other causes of hyperlactaemia (such as diabetes ketoacidosis, heparin treatment, etc.); 5. Severe electrolyte disorder; 6. Taking drugs that increase lactate levels (such as adrenal cortex hormones and trimethoprim).

Design outcomes

Primary

Measure	Time frame
Occurrence of hypotension after induction;Lactate (Lac) level in arterial blood gas at discharge;	—

Secondary

Measure	Time frame
Time to onset of hypotension after induction;Mixed central venous oxygen saturation (ScvO2);	—

Countries

China

Contacts

Public ContactMiao HuiHui

Beijing Shijitan Hospital Affiliated to Capital Medical University

iverymhh@hotmail.com+86 158 0121 3581

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026